Open AccessLipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future
Author(s) -
Alan Chait,
Robert H. Eckel
Publication year - 2016
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2015-3940
Subject(s) - clinical trial , medicine , pcsk9 , intensive care medicine , residual risk , disease , statin , bioinformatics , pharmacology , lipoprotein , cholesterol , biology , ldl receptor
While substantial benefit has accrued with respect to prevention and treatment of atherosclerotic cardiovascular disease (ASCVD) since the advent of statin therapy, much remains unknown and there is considerable need to address residual risk beyond statins. Moreover, many individuals are unable to tolerate statins.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom